AIkido Pharma Inc. (Nasdaq: AIKI) announced an update on its anti-viral platform targeting multiple viruses, including COVID-19 and influenza. Two lead compounds have been optimized for drug-like properties and will soon enter animal testing. A third compound has also been identified for optimization. Initial tests are focused on the Influenza virus, with SARS-CoV-2 testing planned shortly. The company emphasizes its use of AI technology in drug development, showcasing advancements in research.
AIkido Pharma Inc. (Nasdaq: AIKI) has concluded its public offering of 46,875,000 shares at $1.60 per share, generating gross proceeds of $75 million. The offering includes an underwriter's option for an additional 7,031,250 shares. The funds are earmarked for working capital and general corporate purposes. The offering was registered under Form S-3 and is linked to their ongoing development of anti-cancer therapeutics and antiviral platforms.
AIkido Pharma Inc. (Nasdaq: AIKI) has announced an increase in its public offering, now totaling 46,875,000 shares at $1.60 per share, aiming for gross proceeds of approximately $75 million. The offering is expected to close on February 19, 2021, subject to customary conditions. Additionally, the underwriter has a 30-day option to purchase up to 7,031,250 shares at the offering price. Proceeds will be utilized for working capital and general corporate purposes.
AIkido Pharma Inc. (Nasdaq: AIKI) announced an underwriting agreement with H.C. Wainwright & Co. for the purchase of 6,250,000 common shares at $1.60 each. The offering is expected to close around February 19, 2021, pending customary conditions. Additionally, AIkido granted a 30-day option for the underwriter to purchase 937,500 more shares. The net proceeds will be used for working capital and general corporate purposes. This offering is filed under the SEC registration statement effective June 18, 2020.
AIkido Pharma Inc. (Nasdaq: AIKI) announced a Letter of Intent with Silo Pharma to secure a worldwide exclusive sublicense for peptide therapy combined with psilocybin for treating neuroinflammatory diseases in cancer patients. This agreement builds upon a previous licensing agreement dated January 6, 2021, enhancing AIkido's asset portfolio in psilocybin. However, the execution of this proposal may not lead to binding agreements, as it is subject to due diligence and negotiation of definitive terms.
AIkido Pharma Inc. (Nasdaq: AIKI) announced the appointment of Dr. Scott T. Tagawa to its Scientific Advisory Board. Dr. Tagawa is a highly regarded expert in oncology, serving as a Professor of Medicine and Urology at Weill Cornell Medicine. His extensive experience includes leading clinical trials focused on genitourinary cancers. CEO Anthony Hayes emphasized that Dr. Tagawa's expertise will significantly enhance the company's efforts in developing cancer therapies. AIkido continues to pursue innovative treatments, including those for pancreatic cancer and acute leukemia.
AIkido Pharma Inc. (Nasdaq: AIKI) has appointed Dr. Neil H. Bander, M.D., a leading expert in urological oncology from Weill Cornell Medicine, to its Scientific Advisory Board. Dr. Bander, known for developing innovative antibody-targeted therapies for prostate cancer, brings a wealth of experience and patents in the field. CEO Anthony Hayes expressed optimism about leveraging Dr. Bander's expertise to advance AIkido's therapeutic platforms, which aim to address significant unmet medical needs in cancer treatment.
AIkido Pharma Inc. (Nasdaq: AIKI) has secured a $2 million Convertible Promissory Note Purchase Agreement with Convergent Therapeutics, Inc., investing in advanced prostate cancer therapies. Convergent holds exclusive rights to patented technology for peptide receptor radionuclide therapy (PRRT) targeting prostate-specific membrane antigen (PSMA) on cancer cells. Two human clinical trials using Convergent's proprietary drug CONV 01-α are underway, with results expected in Q2 2021. The company anticipates additional trials using dual therapies beginning in February 2021, aiming to enhance treatment efficacy against prostate cancer.
AIkido Pharma Inc. (Nasdaq: AIKI) announced on January 22, 2021, that it has regained compliance with NASDAQ's minimum bid price requirement of $1.00 for continued listing. The Company achieved this following a closing bid price above $1.00 for 10 consecutive business days. CEO Anthony Hayes emphasized their commitment to maintain the NASDAQ listing and their efforts in developing effective pharmaceutical solutions through artificial intelligence technologies.
AIkido Pharma Inc. (Nasdaq: AIKI) announced a Patent License Agreement for psilocybin technology aimed at cancer applications. This innovative technology is backed by four pending patent applications with the U.S. Patent and Trademark Office. Psilocybin, a psychedelic compound, has shown promise in alleviating cancer-related depression and anxiety, with research indicating lasting emotional benefits from single-dose treatments. CEO Anthony Hayes expressed enthusiasm for exploring psilocybin's potential in cancer treatment, which is an expanding area of interest.